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Abstract
Background A considerable minority of patients on waiting lists for kidney transplantation either have no diagnosis (and fall 
into the subset of undiagnosed cases) because kidney biopsy was not performed or histological findings were non-specific, 
or do not fall into any well-defined clinical category. Some of these patients might be affected by a previously unrecognised 
monogenic disease.
Methods Through a multidisciplinary cooperative effort, we built an analytical pipeline to identify patients with chronic 
kidney disease (CKD) with a clinical suspicion of a monogenic condition or without a well-defined diagnosis. Following the 
stringent phenotypical and clinical characterization required by the flowchart, candidates meeting these criteria were further 
investigated by clinical exome sequencing followed by in silico analysis of 225 kidney-disease-related genes.
Results By using an ad hoc web-based platform, we enrolled 160 patients from 13 different Nephrology and Genetics Units 
located across the Piedmont region over 15 months. A preliminary “remote” evaluation based on well-defined inclusion 
criteria allowed us to define eligibility for NGS analysis. Among the 138 recruited patients, 52 (37.7%) were children and 
86 (62.3%) were adults. Up to 48% of them had a positive family history for kidney disease. Overall, applying this workflow 
led to the identification of genetic variants potentially explaining the phenotype in 78 (56.5%) cases.
Conclusions These results underline the importance of clinical exome sequencing as a versatile and highly useful, non-
invasive tool for genetic diagnosis of kidney diseases. Identifying patients who can benefit from targeted therapies, and 
improving the management of organ transplantation are further expected applications.
Keywords Next-generation sequencing · Chronic kidney failure · Transplantation · Renal monogenic disease
Introduction
The importance of genetic contributions in the develop-
ment chronic kidney disease (CKD) is underlined by sev-
eral observations: (1) inherited CKD (IKD) represents a 
high percentage of all CKDs [1–3], (2) the presence of a 
first-degree relative with end stage kidney disease (ESKD) 
confers a sevenfold increased risk of developing kidney fail-
ure [4], and (3) approximately 20–30% of patients report a 
positive family history of CKD in either a first- or second-
degree relative [5, 6]. Thus, IKD represents one of the lead-
ing causes of CKD in children and adults, resulting in an 
increased risk of mortality, the need for organ transplanta-
tion, and high health care costs.
In the paediatric and young adult subset of patients, 
monogenic diseases represent up to 20% of patients who 
develop CKD before 25 years of age, with a variable diag-
nostic yield considering the different CKD categories [7–9].
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Changes in DNA sequence are usually single nucleotide 
variants (SNVs) and small insertions or deletions (indels), 
but larger deletions or insertions called copy number vari-
ants (CNVs) may also occur, particularly in syndromic 
children.
There are several monogenic inherited diseases that cause 
CKD, including developmental disorders, cystic and non-
cystic ciliopathies, and glomerular and tubulo-interstitial 
diseases [10].
Establishing a genetic diagnosis strongly impacts patient 
management and prognosis [8, 11, 12], both by influencing 
treatment choices, as is the case for focal segmental glo-
merulosclerosis (FSGS), and by providing access to spe-
cific drugs, as is the case of vasopressin 2 antagonists for 
patients with autosomal dominant polycystic kidney disease 
(ADPKD). For these reasons, genetic testing is increasingly 
utilized in clinical nephrology due to accessibility of next 
generation sequencing (NGS) technologies [13, 14], which 
are non-invasive and cost-effective, and are becoming part of 
the diagnostic flow for several diseases, due to their decreas-
ing costs, high throughput abilities and reduced sequencing 
times [15]. In this context, NGS technology enables us to 
simultaneously investigate hundreds of genes, thus open-
ing up the possibility to rapidly identify genetic factors that 
underlie IKDs.
This study reports on the set up of an easy-to-use and 
accessible genetic testing platform which can be used to 
characterize undiagnosed cases of CKD eligible for NGS 
testing. Specifically, through this analytical pipeline, we 
aimed at (1) confirming diagnoses, particularly for patients 
in whom a monogenic condition was suspected, (2) finding 
the genetic cause of previously undiagnosed diseases, (3) 
identifying patients who could benefit from targeted thera-
pies and (4) improving the management of organ transplan-
tation, particularly in the living donor setting.
Materials and methods
Patients
This project relies on the multidisciplinary collaboration 
between the ImmunoGenetics and Transplant Biology Ser-
vice (IGTS) of the Città della Salute e della Scienza Uni-
versity Hospital, the Centre of Research of Immunopathol-
ogy and Rare Diseases-CMID, Centre of Coordination of 
the Interregional Network of Rare Diseases of Piedmont 
and Aosta Valley (San Giovanni Bosco Hub Hospital), the 
local ERK-net Member (Nephrology and Dialysis Unit, San 
Giovanni Bosco Hub Hospital and University of Turin), the 
Paediatric Nephrology Dialysis and Transplantation Unit 
(Regina Margherita Children’s Hospital) and the Medical 
Genetics Unit at the San Luigi Gonzaga University Hospital.
The study included 160 patients, recruited in 13 neph-
rology or genetic counselling services across the Pied-
mont Region (north-west Italy, with a population of 
approximately 4,356,000), and coordinated by the IGTS 
between September, 2018 and December, 2019. The IGTS 
performed genetic testing, while recruiting centres are 
reported in Table 1. Overall, these centres follow > 3100 
patients on dialysis and approximately 2500 transplanted 
patients (detailed data are available at www.trapi antip 
iemon te.it).
All patients included in the study provided written 
informed consent.
Set‑up of the platform for genetic diagnosis 
of kidney diseases potentially leading to organ 
failure
We set up a web-based genetic service to provide initial 
genetic counselling to support regional nephrology cen-
tres in Piedmont that requested genetic evaluation (Fig. 1). 
Whenever possible, the referral centre provided IGTS with 
the patient’s medical records including a detailed family 
history, clinical data from routine diagnostic procedures, 
parameters of kidney function, imaging data and biopsy 
results (https ://www.cse.crtpi emont e.it/auth/CRT%20Log 
inGEN new.html).
The platform allowed remote multidisciplinary consulta-
tion in order to decide whether patients were eligible for this 
type of genetic test and to allocate patients with CKD into 
one of the following categories:
(a) Patients with a positive family history for CKD;
(b) Patients for whom genetic confirmation of the clinical 
diagnosis was required;
(c) Patients with CKD with no clinical diagnosis of a defi-
nite disease.
Genetic testing
DNA was extracted from blood samples, evaluated for integ-
rity, and then processed for NGS analysis. Sequencing data 
were analysed by bio-informatics tools to identify, annotate 
and prioritize variants in order to generate a technical report. 
Variants were included in the genetic report that was then 
shared with the referring physician. Sanger sequencing on a 
second independent DNA extraction was performed to con-
firm NGS results. When possible, family segregation studies 
were performed.
The outcome of the genetic test was shared with the clini-
cal team to plan the following steps (Fig. 1). Patients were 
referred to the closest genetic counselling centre.
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Diagnostic cohort
The validity of the platform and of the analytical pipeline 
was tested in a training cohort of 29 blindly tested patients 
for whom clinical and genetic diagnoses were already avail-
able. In each case previous genetic diagnosis was confirmed, 
suggesting that the adopted workflow is effective in the iden-
tification of monogenic kidney disease causative variants.
Of the 160 patients for whom genetic analysis was 
requested, 22 were excluded after a second re-evaluation 
(due to older age or confounding co-morbidities), while 138 
were eligible for NGS analysis. Among them, 52 were chil-
dren (< 18 years old, 37.7%), while 86 were adults (62.3%). 
Seventy-eight/138 (56%) were male [24 in the paediatric 
(46.2%) and 54 (62.8%) in the adult cohort, Table 2]. Sixty-
seven out of 138 patients (48.5% in total; 34.6% in the pae-
diatric and 57.0% in the adult subset) had a positive family 
history for kidney disease (Table 2).
Among the patients who were eligible for NGS, clini-
cal suspicions were as follows: 32 (23.2%) patients who 
presented with clinical features compatible with ciliop-
athy, with or without liver involvement, most of whom 
(30/138; 21.7%) were diagnosed with polycystic kidneys; 
21 patients (15.2%) who presented with a suspected glo-
merular disease, 11 (8%) with tubular diseases, 2 (1.4%) 
with nephrolithiasis/nephrocalcinosis, and 4 (2.9%) with 
haemolytic uraemic syndrome (HUS). Notably, a con-
siderable percentage of these patients (60, 43.4%) pre-
sented with organ failure of unknown origin (Table 2). 
As expected, the great majority of paediatric patients 
(75%) were in stage I CKD, with a glomerular filtration 
rate ≥ 90 ml/min/1.73 m2. Conversely, the majority of adult 
patients were in stages III-IV and presented important 
comorbidities, including diabetes (5.8%) and hyperten-
sion (69.8%) (Table 2).
Clinical exome sequencing and raw data processing
Libraries were prepared using the TruSight One Expanded 
Sequencing Kit (Illumina, San Diego, CA, USA) follow-
ing the manufacturer’s instructions. Raw data were pro-
cessed as reported in the Supplemental Methods (Online 
Resource). The choice of the clinical exome approach was 
dictated by the experimental need of performing a sin-
gle sequencing, followed by flexible in silico analysis of 
organ-specific gene panels (e.g. kidney or liver), further 
tailored on the basis of the clinical suspicion, if avail-
able. The list of causative genes associated with kidney 
disease is updated twice a year, with eventual re-analysis 
of patients with negative genetic reports every 24 months, 
without the need for DNA re-sequencing.
Table 1  NGS cohort
List of recruitment centres (Nephrology Units and Genetics Units) in Piedmont Region, and main features of the cohort included in the pre-
sent study (n = 160). Number of cases, age at recruitment (mean age, min and max age) and eligibility for NGS are listed divided by gender 
(M: male; F: female). Recruiting centres are: San Giovanni Bosco Hospital; Regina Margherita Children’s Hospital; AOU San Luigi Gonzaga: 
Azienda Ospedaliera Universitaria San Luigi Gonzaga; AOU Molinette Hospital: Azienda Ospedaliera Universitaria Molinette Hospital; ASL 
CN1: Azienda Sanitaria Locale—Cuneo, Mondovì and Savigliano; Struttura Semplice Genetics and Molecular Biology, ASL CN1 – Cuneo:ASL 
AL: Azienda Sanitaria Locale—Alessandria; CTO: Centro Traumatologico Ortopedico; ASL TO3: Azienda Sanitaria Locale—Collegno and 
Pinerolo; ASL TO4: Azienda Sanitaria Locale—Ciriè, Chivasso and Ivrea; ASL VCO: Azienda Sanitaria Locale del Verbano Cusio Ossola; AO 
Ordine Mauriziano di Torino: Azienda Ospedaliera Ordine Mauriziano di Torino; ASL NO: Azienda Sanitaria Locale di Novara
Recruitment centre N. of cases 
(n = 160)
Sex n (%) Age at recruitment mean (min–
max)
Eligibility
M F M F M F
Regina Margherita Children’s Hospital 52 24 (46.2) 28 (53.8) 9 (1–21) 8 (0–19) 21 26
AOU San Luigi Gonzaga 19 12 (63.15) 7 (36.85) 41 (21–67) 34 (21–53) 12 6
San Giovanni Bosco Hospital 31 17 (54.8) 14 (45.2) 51 (22–77) 52 (19–67) 15 13
AOU Molinette Hospital 7 4 (57.2) 3 (42.8) 27 (18–35) 45 (32–55) 4 3
ASL CN1 15 10 (66.7) 5 (33.3) 58 (31–73) 53 (30–73) 8 3
ASL AL 6 4 (66.7) 2 (33.3) 46 (23–77) 57 (46–67) 3 2
CTO 2 1 (50) 1 (50) 30 (NA) 60 (NA) 1 0
AO Ordine Mauriziano of Torino 4 1 (25) 3 (75) 37 (NA) 46 (27–57) 0 3
ASL TO3 6 1 (16.7) 5 (83.3) 51 (NA) 76 (72–83) 1 3
ASL TO4 9 7 (77.8) 2 (22.2) 54 (20–69) 48 (45–51) 5 1
SS of genetics Cuneo 3 2 (66.7) 1 (33.3) 56 (54–57) 45 (NA) 2 1
ASL VCO 4 4 (100) 0 (0) 45 (24–57) NA 4 NA
ASL NO 2 2 (100) 0 (0) 33 (21–45) NA 2 NA
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Design of an ad hoc pipeline of analysis to identify 
causative genes
To perform variant calling and identify causative vari-
ants, we designed an ad hoc pipeline of analysis based 
on sequential inclusion/exclusion steps. After reads were 
aligned to the GRCh37 as the reference genome using 
BWA, Isaac Aligner, GATK tools from Illumina, variants 
were processed using Variant Interpreter software, filter-
ing-in mutations on the basis of a phenotype to genotype 
correlation. To this end, we generated a Clinical Pheno-
type to Genotype (CPTG) database by reviewing data from 
the literature and the main databases on inherited/orphan 
diseases (e.g., Online Mendelian Inheritance in Man-
OMIM, Orphanet, PanelApp). CPTG associates clinical 
phenotypes to causative genes and is restricted to a panel 
of 225 genes related to kidney diseases (Supplementary 
Table 1, Online Resource). Variants were firstly filtered by 
using gene lists tailored on the basis of clinical suspicion, 
if available. If a pathogenic or a likely pathogenic variant 
was identified, analysis was stopped, otherwise, all 225 
genes were tested. Synonymous variants were filtered out, 
while inclusion criteria for the remaining variants (non-
synonymous, frame shift, splice site, non-sense) were (1) 
coverage ≥ 20 ×, (2) frequency ≥ 0.3 and (3) frequency in 
the overall population ≤ 1% (to exclude polymorphisms 
which at the time of analysis were not known to be asso-
ciated with clinical phenotype of kidney diseases), as 
reported in the 1000 Genomes Project (1 KG) and Exome 
Aggregation Consortium (ExAC) databases.
Fig. 1  Flowchart of the genetic 
counselling for inherited kidney 
diseases. Patients are recruited 
from the nephrology centres and 
clinical data are shared with the 
ImmunoGenetics and Trans-
plant Biology Service (IGTS) 
through the website for genetic 
counselling for inherited kidney 
diseases. Eligibility is assessed 
based on familiarity, clinical 
suspicion, and available exams. 
For eligible patients, a biologi-
cal sample is processed for NGS 
analysis. A genetic report is 
generated and then sent back to 
the referring physician. The last 
step provided by the Service is 
post-test genetic counselling
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Inheritance mode was considered next. Specifically, if 
heterozygous mutations were found in genes associated 
with autosomal recessive (AR) diseases, they were care-
fully re-analysed to check for variants in genes known to be 
responsible for clinical phenotype in association with other 
genes (digenic diseases).
Filtered variants were then annotated (1) on the basis of 
the main public databases reporting associations between 
Table 2  Characteristics of 
patients eligible for NGS
Clinical details of the NGS-eligible study cohort (138 patients). Eligible patients are sub-divided on the 
basis of their gender, presence of a positive family history for kidney diseases, age at onset (mean, min 
and max age), clinical suspicion provided by clinicians at recruitment, results from genetic testing, chronic 
kidney disease (CKD) stage, availability of kidney biopsy or imaging data, glomerular filtration rate and 
other features. Number and percentage of cases are shown. CAKUT: congenital abnormalities of kidney 
and urinary tract
Eligible cohort (n = 138)
Features Paediatric (n = 52) Adults (n = 86)
Sex
 Female n (%) 28 (53.8) 32 (37.2)
 Male n (%) 24 (46.2) 54 (62.8)
Positive family history n (%) 18 (34.6) 49 (57.0)
Age at onset mean (min–max) 3 (0–14) 37 (0–80)
Clinical suspicion
 CAKUT n (%) 3 (5.8) 0 (0)
 Tubular disease n (%) 5 (9.6) 6 (7)
 Ciliopathies n (%) 13 (25) 19 (22.1)
 Nephrolithiasis/nephrocalcinosis n (%) 1 (1.9) 1 (1.2)
 Glomerular disease n (%) 9 (17.3) 12 (13.9)
 Haemolytic uraemic syndrome n (%) 1 (1.9) 3 (3.5)
 Organ failure for unknown reasons n (%) 18 (34.6) 42 (48.8)
 Others n (%) 2 (3.9) 3 (3.5)
Genetic diagnosis
 Cases with variants identified and in line with the 
clinical phenotype
30 (57.7) 48 (55.8)
 Cases with no variants identified or incompatible with 
the clinical phenotype
22 (42.3) 38 (44.2)
CKD stage
 I 39 (75) 34 (39.6)
 II 6 (11.5) 8 (9.3)
 III 2 (3.9) 15 (17.5)
 IV 1 (1.9) 11 (12.8)
 V 0 (0) 10 (11.6)
 Dialysis 0 (0) 4 (4.6)
 Transplanted 4 (7.7) 4 (4.6)
Kidney biopsy performed 15 (28.8) 29 (33.7)
Imaging 41 (78.8) 69 (80.2)
Glomerular filtration rate (ml/min/1.73 m2)
 ≥ 90 39 (75) 34 (39.6)
 60–89 6 (11.5) 7 (8.1)
 30–59 2 (3.9) 16 (18.6)
 15–29 1 (1.9) 12 (13.9)
 < 15 4 (7.7) 17 (19.8)
Other characteristics
 Diabetes 0 (0) 5 (5.8)
 Hypertension 8 (15.4) 60 (69.8)
 Extra-renal features 21 (40.4) 28 (32.6)
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gene variants and clinical phenotype, including OMIM, 
ClinVar, Human Genome Mutation Database (HGMD), the 
Genome Aggregation Database (GnomAD), database of 
single nucleotide polymorphism (dbSNP), Varsome, Exome 
Variant server (EVS) and (2) by considering the impact on 
protein structure or function by in silico prediction tools.
Variants classified as “pathogenic C5” and “likely path-
ogenic C4” were always included in the genetic report, 
as were “variants of unknown significance (VUS) C3” in 
genes associated with diseases with autosomal dominant 
(AD) or X-linked recessive (in males) mode of inheritance, 
while C3 variants in genes associated with diseases having 
AR mode of inheritance were reported only if they were 
in line with the clinical phenotype (Fig. 2). Confirmation 
by Sanger sequencing and family segregation studies were 
performed whenever possible.
Classification of the identified variants and their 
description in the genetic report were in line with The 
American College of Medical Genetics and Genomics 
(ACMG) policy statement on clinical sequencing (https 
Fig. 2  Ad hoc pipeline of 
analysis. The pipeline is made 
up of several consecutive steps: 
phenotype-genotype correla-
tion, filtering-in based on type 
of variant/frequency and disease 
list, inheritance model, variant 
annotation(s), manual curation 
and reporting of variants. For 
each step, specific actions and 
tools are indicated. BWA Bur-
rows–Wheeler aligner, GATK 
genome analysis toolkit, CPTG 
clinical phenotype to genotype 
database, Alt fr altered allele 
frequency, 1 KG 1000 Genomes 
Project, ExAC Exome Aggrega-
tion Consortium, OMIM: online 
mendelian inheritance in men, 
HGMD human genome muta-
tion database, GnomAD the 
genome aggregation database, 
dbSNP database of single 
nucleotide polymorphism, EVS 
exome variant server
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://www.acmg.net/) and with the Italian Society of Human 
Genetics (SIGU) [16].
Costs related to the NGS approach for the diagnosis 
of genetic kidney diseases
Overall, the cost of analysis per sample was differenti-
ated on the basis of clinical suspicion: if a specific disease 
with < 3 causative genes was suspected the cost charged to 
the national health system was 1062 euros. For all other 




Overall, by adopting the reported bio-informatics analy-
sis pipeline, we detected 129 variants in 65 genes, with 28 
patients carrying more than one variant. Interestingly, of all 
these variants, only 3 were recurrently present in more than 
one patient, while all the others were uniquely carried by 
individual patients.
Genetic variants were classified according to ACMG 
guidelines. In 78/138 (56.5%) patients, at least one variant 
was compatible with the clinical phenotype, as indicated in 
Table 3. In the remaining (60/138; 43.5%) patients, vari-
ants were either not present, or heterozygous in autosomal 
recessive genes or they were not in line with the clinical 
phenotype (not shown). Among patients for whom we iden-
tified variants compatible with the phenotype, 43 (55.1%) 
presented heterozygous variants in genes associated with 
autosomal dominant diseases, 16 (20.5%) were homozygous 
or compound heterozygous with variants in genes associ-
ated with autosomal recessive disease (among which 1 was 
a copy number loss) and 11 (14.1%) were characterized by 
variants in genes mapping on chromosome X (among which 
2 were copy number losses). Lastly, 8 patients (10.3%) pre-
sented with variants in genes with both an autosomal domi-
nant and autosomal recessive mode of inheritance (Table 3; 
Fig. 3a).
When considering all 129 variants in our cohort, 74 
(57.4%) were missense, 10 (7.8%) nonsense, 19 (14.7%) 
frameshift, 7 (5.4%) indel, 15 (11.6%) variants affected the 
splicing regions and 4 (3.1%) were copy number variants 
(Fig. 3b).
Furthermore, when classifying all the variants identified 
by clinical exome sequencing according to ACMG guide-
lines to describe mutations in genes that cause Mendelian 
disorders, we found 27 variants defined as “pathogenic C5” 
(21.0%), 35 as “likely pathogenic C4” (27.1%) and 67 as 
“variants of unknown significance C3” (51.9%) (Table 3; 
Fig. 3c), considering that 28 patients were characterized 
by the presence of more than one variant with different 
classification.
Association between clinical and molecular 
diagnosis
The diagnosed cases, defining patients for whom genetic 
variants in line with the clinical phenotype were identified, 
were differentially distributed when considering the clinical 
suspicion categories (Table 3; Fig. 4). A high detection rate 
was obtained in glomerular diseases (14/21 cases; 66.7%), 
especially Alport disease and ciliopathies (22/32 cases; 
68.8%), particularly ADPKD, while for tubular diseases 
and HUS, causative variants were identified in 4 out of 11, 
and 1 out of 4 cases, respectively. In the nephrolithiasis and 
nephrocalcinosis subset, one patient presented with a poten-
tially causative variant in a relevant gene. With regard to 
the remaining categories, phenotype-related variants were 
detected in 50% of cases (4 out of 8). Moreover, our NGS 
approach identified the genetic culprit in a significant pro-
portion of cases presenting with organ-failure of unknown 
origin (32/60 cases; 53.3%).
Among the cohort of patients with variants identified by 
NGS, all cases were validated by Sanger sequencing per-
formed on a second independent aliquot of DNA. When 
possible, specifically in 23/52 paediatric patients, variant(s) 
were validated in the proband and in the trio. This analy-
sis confirmed the segregation of variants in the family and 
helped clarify the clinical significance of “C3 VUS”.
Discussion
In this study we describe an ad hoc-designed web-based 
platform built to connect regional Nephrology and Genetics 
centres to a centralized facility that provides genetic test-
ing for patients with CKD. Herein we share our preliminary 
15-month experience in applying this targeted sequencing 
to achieve a genetic diagnosis for undiagnosed patients with 
CKD in a well-selected cohort of patients from north-west 
Italy.
Our study presents two points that are worthy of inter-
est. First, the feasibility of a centralized platform to support 
multidisciplinary consultation in patients with a high clinical 
suspicion of a monogenic condition. Second, an improve-
ment in the diagnostic rate of patients with CKD and no 
previous definite diagnosis.
Our approach is based on a web-based platform as an 
extension of the existing regional transplant network. By 
using this platform, we attempted to optimize multidisci-
plinary consultations for patients for whom a monogenic 
condition was suspected. In order to explain the philosophy 
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category Gene ID MoI
All 








COL4A5 XL Hem NM_033380.2 c.1871G>A; p.(Gly624Asp) missense C5
COL4A3 AR/AD Het NM_000091.4 c.3196C>T; p.(Pro1066Ser) missense C3
#2 Ciliopathies PKD1 AD Het
NM_001009944.
2 c.8594G>A; p.(Arg2865Gln) missense C3
#3* Unknown reasons DSTYK AD Het NM_015375.2 c.2215C>T; p.(Arg739Trp) missense C3
#4*
Unknown 
reasons SLC5A2 AD Het NM_003041.3 c.1961A>G; p.(Asn654Ser) missense C5
#5* Ciliopathies
HNF1B AD Het NM_000458.2 c.826C>T; p.(Arg276*) nonsense C5
PKD1 AD Het
NM_001009944.
2 c.7490-5C>G splicing C3
#6* Glomerular disease
COL4A5 XL Hem NM_033380.2 CNV loss C5
COL4A6 XL Hem NM_001847.3 CNV loss C5
#7* Ciliopathies
PKD1 AD Het NM_001009944.
2
c.8830G>T; p.(Val2944Phe) missense C3





#8* Glomerular disease WT1 AD Het NM_024426.4 c.1373G>A; p.(Arg458Gln) missense C3












m NM_024753.4 c.626C>T; p.(Pro209Leu) missense C5
SLC4A1 AD/AR Het NM_000342.3 c.457C>A; p.(Leu153Met) missense C3
#12
Glomerular 
disease INF2 AD Het NM_022489.3 c.212A>C; p.(Gln71Pro) missense C3






SLC12A3 AR Het NM_000339.2 c.1964G>A; p.(Arg655His) missense C5
SLC12A3 AR Het NM_000339.2 c.965C>T p.(Ala322Val) missense C3
SLC12A3 AR Het NM_000339.2 c.1336-8C>A splicing C3
#15 Unknown reasons
PKD1            AD Het NM_001009944.
2
c.1295C>T; p.(Ala432Val) missense C4









BBS2             AR Het NM_031885.3 c.1864C>T; p.(Arg622*) stop C5










#19 Unknown reasons PKD1 AD Het
NM_001009944.





PKD1            AD Het
NM_001009944.
2 c.11614G>A; p.(Glu3872Lys) missense C4
PKD1      AD Het NM_001009944.2 c.5600A>G ;p.(Asn1867Ser) missense C3
#21
Unknown 
reasons COL4A4        
AR/A
D Het NM_000092.4 c.755G>A; p.(Gly252Asp) missense C4
#22 Unknown 
reasons
PKD1 AD Het NM_001009944.2
c.7394_7396delTGTinsCGC; 
p.(LeuSer2465ProPro) indel C3
PKHD1 AR Het NM_138694.3 c.10609A>C; p.(Asn3537His) missense C3
#23 Unknown reasons PKD2 AD Het NM_000297.3 c.1096-6A>T splicing C3
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D Het NM_000092.4 c.693+2T>C splicing C3
#25 Unknown reasons COL4A5        XL Hem NM_033380.2 c.520G>C; p.(Gly174Arg) missense C5
#26*
Unknown 
reasons CLCN5 XL Hem
NM_001127898.
3 c.1869delG; p.(Arg624Glyfs*32) 
frameshif
t C4







NM_000091.4 c.3592G>A; p.(Gly1198Ser) missense C3




Het NM_000092.4 c.1460-6G>A splicing C3
CFH AR/AD Het NM_000186.3 c.3134-7T>C splicing C3
#31* Unknown 
reasons
NPHS1 AR Het NM_004646.3 c.260G>T; p.(Gly87Val) missense C3






m NM_000030.2 c.33dupC; p.(Lys12Glnfs*156)
frameshif
t C5
HOGA1 AR Het NM_138413.3 c.700+5G>T splicing C5
#33
Unknown 
reasons PKD1            AD Het
NM_001009944.
2 c.8990G>T; p.(Ser2997Ile) missense C4
#34 Unknown reasons ACTN4 AD Het NM_004924.5 c.459C>G; p.(Phe153Leu) missense C3
#35 Unknown reasons
COL4A1 AD Het NM_001845.4 c.2566C>T; p.(Gln856*) stop C4
SLC34A1 AR/AD Het NM_003052.4 c.840+1G>C splicing C4
DSTYK AD Het NM_015375.2 c.2215C>T;  p.(Arg739Trp) missense C3
#36* HUS CFHR1 -CFHR3 AR
Ho




1 AR Het NM_001692.3 c.1037C>G; p.(Pro346Arg) missense C4
ATP6V1B
1 AR Het NM_001692.3 c.33delG; p.(Leu12Serfs*8)
frameshif
t C4
#38 Ciliopathies SLC5A2 AD Het NM_003041.3 c.800G>A; p.(Arg267Gln) missense C3
#39 Ciliopathies TSC2 AD Het NM_000548.4 c.2072G>A; p.(Arg691His) missense C3
#40
Glomerular 
disease COL4A5 XL Hem NM_033380.2 c.3268T>C; p.(Tyr1090His) missense C3





R Het NM_000091.4 c.3437G>A p.(Gly1146Glu) missense C3





R Het NM_000091.4 c.1006G>Tp.(Gly336Cys) missense C4
#45 Glomerular disease INF2 AD Het NM_022489.3
c.1280_1285delCACCCC 
p.(Pro427_Pro428del) indel C3
#46 Ciliopathies PKD2 AD Het NM_000297.3 c.1319G>C;p.(Arg440Thr) missense C3
#47 Ciliopathies
TSC2 AD Het NM_000548,4 c.1078A>G; p(Ile360Val) missense C3
CYP24A1 AR Het NM_000782,4 c.1186C>T; p.(Arg396Trp) missense C5







#49 Ciliopathies PKD1 AD Het
NM_001009944.
2 c.7119C>G; p.(Cys2373Trp) missense C3
#50 Ciliopathies PKD1 AD Het NM_001009944.2 c.8293C>T; p.(Arg2765Cys) missense C3
#51 Unknown 
reasons
COL4A5 XL Hem NM_033380.2 c.2087G>A; p.(Gly696Asp) missense C3
#52 Ciliopathies
PKD1 AD Het NM_001009944.2 c.7288C>T; p.(Arg2430*) nonsense C5
PKD1 AD Het NM_001009944.
2
c.9454C>T; p.(Arg3152Trp) missense C3
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2 c.1007T>C; p.(Leu336Pro) missense C4
SLC4A1 AD Het NM_000342.3 c.118G>A; p.(Glu40Lys) missense C4
#54
Unknown 
reasons PKD1 AD Het
NM_001009944.











1 c.756G>A p.(Gln252=) splicing C3




2 c.5963_5964insG p.(Glu1989*) nonsense C4





NM_014625.2 c.855_856delAA; p.(Arg286Thrfs*17) frameshif
t
C4
#58 Ciliopathies PKD2 AD Het NM_000297.3 c.1548+1G>A splicing C4
#59
Tubular 
disease PAX2 AD Het NM_003990.3 c.821delC p.(Pro274Leufs*23) 
frameshif
t C4
#60 Ciliopathies PKD1 AD Het NM_001009944.2 c.6424C>T; p.(Gln2142*) nonsense C4
#61* Ciliopathies
PKHD1 AR Het NM_138694.3 c.131-1G>A splicing C4





D Het NM_014270.4 c.313G>A; p.(Gly105Arg) missense C5
#63* Unknown reasons
SALL1 AD Het NM_002968.2 c.475_477dupAGC; p.(Ser159dup) indel C3
GRIP1 AD Het NM_021150.3 c.934T>C; p.(Cys312Arg) missense C3
#64* Unknown 
reasons


















PKHD1 AR Het NM_138694.3 c.4450G>A; p.(Ala1484Thr) missense C3
PKHD1 AR Het NM_138694.3 c.12027C>G; p.(Tyr4009*) nonsense C3
#68 Glomerular 
disease
COL4A5 XL Hem NM_033380.2 c.4629C>A; p.(Tyr1543*) stop C4
#69
Tubular 
disease WNK4 AD Het NM_032387.4 c.3554G>A; p.(Arg1185His) missense C3
#70 Glomerular 
disease
COL4A6 XL Hem NM_001847.3 c.3010C>G; p.(Pro1004Ala) missense C3
COL4A3 AD/AR Het NM_000091.4 c.510A>T; p.(Lys170Asn) missense C3
COL4A4 AD/A
R
Het NM_000092.4 c.594+5G>A splicing C3
#71
Unknown 











#73 Ciliopathies TSC1 AD Het NM_000368.4 c.2626-3delC splicing C3
#74 Ciliopathies PKD1 AD Het NM_001009944.2 c.6778_6780 delATT; p.(Ile2260del) deleon C4
#75* Ciliopathies
PKHD1 AR Het NM_138694.3 c.4882C>G; p.(Pro1628Ala) missense C4
PKHD1 AR Het NM_138694.3 c.9464A>G; p.(Tyr3155Cys) missense C3
#76 CAKUT SLC3A1
AR/A
D Het NM_000341.3 c.1400T>C; p.(Met467Thr) missense C5
#77* Glomerular 
disease
CUBN AR Hom NM_001081 c.164C>T; p.(Thr55Met) missense C3
KANK4 NA Het NM_181712.4 c.2401T>C; p.(Tyr801His) missense C3
#78* Tubular 
disease
OCRL XL Hem CNV loss C5
The table shows the list of 78 patients in whom a potentially diagnostic genetic variant may be present Asterisks indicate the family segregation 
studies that were carried out. When more than one variant is present, the ones potentially explaining the clinical phenotype are highlighted in blue
MoI mode of inheritance, All. Freq allele frequency, Ref Seq reference sequence, AD autosomal dominant, AR autosomal recessive, XL X-linked, 
Het heterozygous, Hom homozygous, Hem hemizygous, CNV copy number variation, Indel insertion/deletion, HUS haemolytic uraemic syndrome
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and the practical issues of the platform two training courses 
for the nephrologists of the recruiting centres were organized 
in 2019. Moreover, in order to reduce waiting time, a rapid 
(mean waiting time of 3 days), web-based, pre-test genetic 
assessment was offered, with no need for patients to have 
in-person genetic counselling.
Patients’ samples and informed consent were obtained 
through the Nephrology or Genetic Counselling Services, 
thus overcoming the need for the patient and his/her fam-
ily to travel. The connection of the IGTS to the various 
nephrology Units throughout the Region was made pos-
sible by a capillary network of the Regional Centre for 
Transplantation. To speed up the connection between “the 
edge” and “the centre” of the hub, an IT platform was set-up 
allowing clinicians and geneticists to share clinical data and 
genetic reports. Recruited patients were initially evaluated 
by geneticists for their eligibility for NGS based on several 
criteria including family history and clinical data. Analyses 
of sequencing data and identification of the causative vari-
ants were performed based on an ad hoc pipeline.
Close to 300 patients were recruited between September, 
2018 and March, 2020, and a final genetic report was avail-
able for 160 of them after a median time for genetic analysis 
of 6 months. The remaining 140 patients were in different 
steps of the diagnostic process at the time of this interim 
analysis.
In this study, we performed clinical exome sequencing 
followed by an in-silico analysis focused on selective genes 
in a cohort of 138/160 recruited patients affected by CKD. 
In 56.5% of cases NGS analysis was able to determine the 
molecular genetic cause of the disease, revealing 129 vari-
ants in 65 genes. These results are on average higher than 
those reported in the literature, likely due to patient pre-
selection on the basis of positive family history and clinical 
suspicion [9].
With regard to the need to provide genetic confirmation 
of a previous clinical diagnosis, NGS analysis was able to 
confirm 68.8% of ciliopathies, a percentage that is in line 
with previous publications [17]. The detection rate was 
higher in glomerular diseases (66.7% vs. 14% reported in 
the literature) and nephrolithiasis (50% vs. 15–30%) [9]. 
This high percentage is due to selection of patients with a 
suspicion of Alport disease, at least based on biopsy results. 
In contrast, the percentage of solved cases presenting with 
Congenital Anomalies of the Kidneys and of the Urinary 
Tract (CAKUT) and haemolytic uraemic syndrome was 
quite low, with a considerable number of cases remaining 
undiagnosed. A reason for these results could be related to 
either the genetic heterogeneity of the disease, with many 
causative genes still to be identified, or to non-genetic causes 
[8].
In a considerable subset of the recruited cohort, patients 
were referred to genetic analysis because of a kidney disease 
of unknown origin. As expected, based on previous experi-
ence from other centres, this approach proved to be efficient 
in revealing causative variants: in a significant number of 
these cases, we were able to identify genetic variants that 
were in line with the clinical phenotype, thus helping clini-
cians in the management of these patients. Surprisingly, in 
our cohort, the percentage of patients for whom a genetic 
variant in line with the clinical phenotype was identified 
was not so different when considering paediatric (57.7%) 




Fig. 3  Classification of the identified variants in the Piedmont cohort. 
a Number and percentage of patients having an autosomal dominant, 
autosomal recessive or X-linked disease on the basis of NGS-identi-
fied variants. b Classification of the identified variants as missense, 
nonsense, frameshift, insertion/deletion (indel) or affecting the splice 
site. Copy number variants (CNVs) are also represented. Number and 
percentage of variants belonging to the various categories is indi-
cated in brackets. c Number and percentage of variants classified on 
the basis of the American College of Medical Genetics guidelines, 
considering pathogenic C5, likely pathogenic C4 and variants of 
unknown significance (VUS, C3)
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adult cohort was carefully selected for patients with a strong 
suspicion of an underlying genetic condition. In line with the 
selection of the cohort is the limited number of cases that 
were re-classified. Of note, 18 out of 60 patients lacking a 
definitive diagnosis were children. NGS application to this 
subgroup appeared to be a useful tool as it resulted in the 
detection of variants in an appreciable number of cases (10 
out of 18; 55.5%), and provided a genetic explanation for 
their clinical condition.
Establishing a precise genetic diagnosis, especially for 
childhood-onset CKD, allows for pre-emptive screening for 
extra-renal manifestations. In some cases, the kidneys are 
not the only affected organs and variants in selective genes 
may cause syndromic diseases. In other cases, the phenotype 
is the result of hypomorphic mutations leading to variable 
expressivity and thus resulting in varying clinical manifesta-
tions. Moreover, it must be kept in mind that some disease-
causing genes may manifest as de novo variants, with a 
non-inherited history. Finally, because of the high phenotype 
heterogeneity, several forms of IKDs may become evident 
only later in life, when patients reach ESKD. Establishing 
an early and accurate diagnosis will result in better patient 
management, improving quality of life, and avoiding useless 
treatments. Furthermore, it allows early screening of at-risk 
family members.
This technical approach has some known drawbacks. In 
exome sequencing, variants occurring in the intronic and 
promoter regions cannot be identified, and not all genomic 
regions are equally covered. Moreover, regions with high 
guanine-cytosine content, and high sequence homology with 
pseudogenes may be missed. Even detection of copy number 
variations or structural variants can be difficult and need to 
be further validated by alternative approaches. An additional 
limitation of this type of sequencing is represented by the 
detection of pathogenic variants in the MUC-1 gene, repre-
sented by duplicated C or inserted A nucleotides within the 
Fig. 4  Clinical and genetic diagnosis in the Piedmontese CKD 
cohort. Patient cohort is divided on the basis of the clinical suspi-
cion (inner pie). Number and percentage of patients for each macro-
category are indicated outside the outer pie, which instead represents 
the percentage of patients with identified causative variants (variants 
in line with the clinical phenotype) and patients with no causative 
variants identified or variants incompatible with the clinical pheno-
type for each disease category. Specific percentages of these cases are 
reported on the right with a colour-code legend
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coding variable-number tandem repeats (VNTRs), which 
cannot be identified by exome or genome sequencing, but 
can only be identified by targeted analysis [18]. Finally, we 
have to underline that some genes known to be associated 
with specific CKD phenotypes are not included in this clini-
cal exome panel, and thus variants occurring in these genes 
cannot be investigated. It is also worth pointing out that the 
list of genes involved in CKD is progressively expanding 
[9], therefore, applying the updated list of genes in the re-
analysis of previously sequenced patients who received a 
non-conclusive or negative genetic diagnosis may result 
in the identification of causative genes. Likewise, variants 
of unknown significance identified by NGS can be re-clas-
sified over time, benefiting from periodic updates. These 
latter observations also justify the choice of the experimen-
tal approach adopted in this study based on clinical exome 
sequencing instead of limited and fixed targeted sequencing 
panels.
In conclusion, this study shows that clinical exome 
sequencing is a non-invasive, highly effective tool for 
genetic diagnosis if the program is supported by careful can-
didate selection. It can be useful in identifying patients who 
would benefit from targeted therapies, such as vasopressin 
2 antagonists in the case of ADPKD. Furthermore, it may 
impact on therapy choices, particularly in the case of FSGS, 
and in the selection of the ideal family member as a kidney 
donor. This approach is especially applicable in geographic 
areas where the interaction between a robust nephrological 
network and genetic facilities is long-standing. Lastly, it can 
be cost-effective, especially if it is applied early in the diag-
nostic flow of the patient as it may (1) provide an early diag-
nosis and (2) avoid unnecessary treatment, while guiding the 
nephrologist towards the best management of the patient. 
For all these reasons, this approach could become, in well-
characterized cases, an essential step of the diagnostic path.
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